Sigma-1 Receptor as a Novel Therapeutic Target in Diabetic Kidney Disease
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252413327 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Dora B Balogh und 9 weiteren Autor:innen. Beteiligte Einrichtung: MTA-SE Lendület "Momentum" Diabetes Research Group, 1083 Budapest, Hungary. Hauptthemen laut MEDLINE: Sigma-1 Receptor, Receptors, sigma, Diabetic Nephropathies, Rats, Wistar. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hungarian Academy of Sciences, National Research, Development and Innovation Office, New National Excellence Program of the Ministry for Culture and Innovation.
Abstract (Originalsprache)
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease. Current treatments for DKD do not halt renal injury progression, highlighting an urgent need for therapies targeting key disease mechanisms. Our previous studies demonstrated that activating the Sigma-1 receptor (S1R) with fluvoxamine (FLU) protects against acute kidney injury by inhibiting inflammation and ameliorating the effect of hypoxia. Based on these, we hypothesized that FLU might exert a similar protective effect in DKD. Diabetes was induced in male Wistar rats using streptozotocin, followed by a seven-week FLU treatment. Metabolic and renal parameters were assessed along with a histological analysis of glomerular damage and fibrosis. The effects of FLU on inflammation, hypoxia, and fibrosis were tested in human proximal tubular cells and normal rat kidney fibroblasts. FLU improved renal function and reduced glomerular damage and tubulointerstitial fibrosis. It also mitigated inflammation by reducing TLR4, IL6, and NFKB1 expressions and moderated the cellular response to tubular hypoxia. Additionally, FLU suppressed TGF-β1-induced fibrotic processes and fibroblast transformation. These findings suggest that S1R activation can slow DKD progression and protect renal function by modulating critical inflammatory, hypoxic, and fibrotic pathways; therefore, it might serve as a promising novel drug target for preventing DKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MTA-SE Lendület "Momentum" Diabetes Research Group, 1083 Budapest, Hungary.
- Pediatric Center, MTA Center of Excellence, Semmelweis University, 1083 Budapest, Hungary.
- Department of Surgery, Transplantation, and Gastroenterology, Semmelweis University, 1082 Budapest, Hungary.
ORCID-Profile: Dora B Balogh, Adar Saeed, Tamas Lakat, Lilla Lenart, Laszlo J Wagner
Förderung
- Hungarian Academy of Sciences
- National Research, Development and Innovation Office
- New National Excellence Program of the Ministry for Culture and Innovation
- Ministry of Innovation and Technology of Hungary
Zitieren
APA
Balogh, D. B., Hodrea, J., Saeed, A., Cserhalmi, M., Rozsahegyi, A., Lakat, T., Lenart, L., Szabo, A. J., Wagner, L. J., & Fekete, A. (2024). Sigma-1 Receptor as a Novel Therapeutic Target in Diabetic Kidney Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252413327
Vancouver
Balogh DB, Hodrea J, Saeed A, Cserhalmi M, Rozsahegyi A, Lakat T, et al. Sigma-1 Receptor as a Novel Therapeutic Target in Diabetic Kidney Disease. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252413327
BibTeX
@article{Balogh2024,
author = {Balogh, Dora B and Hodrea, Judit and Saeed, Adar and Cserhalmi, Marcell and Rozsahegyi, Alexandra and Lakat, Tamas and Lenart, Lilla and Szabo, Attila J and Wagner, Laszlo J and Fekete, Andrea},
title = {Sigma-1 Receptor as a Novel Therapeutic Target in Diabetic Kidney Disease},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252413327}
}
EUVIMED